Horm Metab Res 2017; 49(09): 654-659
DOI: 10.1055/s-0043-115645
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas

Pedro Iglesias
1   Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain
,
Karina Arcano
1   Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain
,
Vanessa Triviño
2   Department of Endocrinology, Hospital Universitario A Coruña, A Coruña, Spain
,
Paula García-Sancho
3   Department of Endocrinolgy, Hospital Universitario de Bellvitge, L’ Hospitalet de Llobregat, Barcelona, Spain
,
Juan José Díez
1   Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain
4   Department of Medicine, Universidad de Alcalá de Henares, Madrid, Spain
,
Carles Villabona
3   Department of Endocrinolgy, Hospital Universitario de Bellvitge, L’ Hospitalet de Llobregat, Barcelona, Spain
,
Fernando Cordido
2   Department of Endocrinology, Hospital Universitario A Coruña, A Coruña, Spain
› Author Affiliations
Further Information

Publication History

received 28 February 2017

accepted 29 June 2017

Publication Date:
31 July 2017 (online)

Abstract

The objective of the study was to assess the prevalence and clinical features of incidentally discovered clinically non-functioning pituitary adenoma (CNFPA) and to analyze its natural history. A multicenter retrospective study in patients diagnosed with incidental CNFPA periodically followed-up in 3 specialized neuroendocrinology units from 1992 to 2015 was performed. Out of a total of 189 CNFPA patients, 57 cases (30.1%; 29 women; age at diagnosis 55.8±16.7 years) were incidental. Most patients (n=55, 96.5%) were diagnosed by magnetic resonance imaging (MRI). A sum of 71.9% (n=41) were macroadenomas; 2 of them (3.5%) were giant adenomas (≥4 cm). Patients with macroadenomas were older than those with microadenomas (59.5±16.7 vs. 46.4±18.1 years, p=0.007). Macroadenomas were more common in men (85.7% vs. 58.6%, p=0.023). Twenty-eight patients (49.1%) showed suprasellar extension; of these, 19 were accompanied by chiasmatic compression. Hypopituitarism was present in 14 (24.6%) patients; which was partial in 13 patients (22.8%) and complete in one patient (1.8%). The gonadal axis was the most frequently affected (n=13, 22.8%). Twenty four patients (42.1%) underwent surgery. Of the non-operated patients, 26 patients could be evaluated morphologically after a median follow-up of 15.5 months (interquartile range, 5.7–32.7 months). No significant changes were found in the maximum tumor diameter at the end of follow-up (1.2±0.6 vs 1.2±0.7 cm). The majority of CNFPAs evaluated (n=23, 88.5%) did not show any changes in size. In 2 cases (7.7%) tumor size decreased, and in one patient (3.8%) increased. In our series of CNFPA patients, approximately one-third were incidental. These tumors were diagnosed by MRI preferably from the 5th decade of life without sex predilection. Most of them were macroadenomas, more commonly diagnosed in men and at an older age, compared to microadenomas. The suprasellar extension with chiasmatic compression and hypopituitarism were frequent at diagnosis. Most of the non-operated incidental CNFPAs remain with stable tumor size over time, growth being an unusual event.

 
  • References

  • 1 Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: A systematic review. Cancer 2004; 101: 613-619
  • 2 Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014; 117: 379-394
  • 3 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012; 14 (Suppl. 05) v1-49
  • 4 Shibui S. The present status and trend of brain tumors based on the data of the Brain Tumor Registry of Japan. Brain Nerve 2012; 64: 286-290
  • 5 Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41: 359-364
  • 6 Molitch ME. Diagnosis and treatment of pituitary adenomas: A review. JAMA 2017; 317: 516-524
  • 7 Molitch ME. Nonfunctioning pituitary tumors. Handb Clin Neurol 2014; 124: 167-184
  • 8 Scangas GA, Laws Jr. ER. Pituitary incidentalomas. Pituitary 2014; 17: 486-491
  • 9 Vasilev V, Rostomyan L, Daly AF, Potorac I, Zacharieva S, Bonneville JF, Beckers A. Management of endocrine disease: Pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis. Eur J Endocrinol 2016; 175: R171-R184
  • 10 Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML. Endocrine Society. Pituitary incidentaloma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 894-904
  • 11 Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999; 28: 81-117 vi
  • 12 Esteves C, Neves C, Augusto L, Menezes J, Pereira J, Bernardes I, Fonseca J, Carvalho D. Pituitary incidentalomas: Analysis of a neuroradiological cohort. Pituitary 2015; 18: 777-781
  • 13 Sivakumar W, Chamoun R, Nguyen V, Couldwell WT. Incidental pituitary adenomas. Neurosurg Focus 2011; 31: E18
  • 14 Molitch ME. Management of incidentally found nonfunctional pituitary tumors. Neurosurg Clin N Am 2012; 23: 543-553
  • 15 Bancos I, Natt N, Murad MH, Montori VM. Evidence-based endocrinology: Illustrating its principles in the management of patients with pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 2012; 26: 9-19
  • 16 Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA. Incidentally discovered pituitary lesions: High frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol (Oxf) 1999; 51: 109-113
  • 17 Fainstein Day P, Guitelman M, Artese R, Fiszledjer L, Chervin A, Vitale NM, Stalldecker G, De Miguel V, Cornalo D, Alfieri A, Mallea Gil MS. Retrospective multicentric study of pituitary incidentalomas. Pituitary 2004; 7: 145-148
  • 18 Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Diez JJ. Prolactinomas in men: A multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf) 2012; 77: 281-287
  • 19 Chen CC, Carter BS, Wang R, Patel KS, Hess C, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z, Zada G, Aghi MK. Congress of neurological surgeons systematic review and evidence-based guideline on preoperative imaging assessment of patients with suspected nonfunctioning pituitary adenomas. Neurosurgery 2016; 79: E524-E526
  • 20 Fleseriu M, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G. Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 2016; 79: E527-E529
  • 21 Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006; 65: 524-529
  • 22 Hong JW, Lee MK, Kim SH, Lee EJ. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine 2010; 37: 140-147
  • 23 Lucas JW, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G. Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 2016; 79: E533-E535